Relation of C-reactive protein to features of the metabolic syndrome in normal glucose tolerant, impaired glucose tolerant, and newly diagnosed type 2 diabetic subjects

Diabetes and Metabolism

Volumn 29, Issue 1, 2003, Pages 65-71

  Guerrero Romero, F ^a,b,c   Rodriguez Moran M ^a,b  

^a Clin Epidemiol Mex Social S I   (Mexico)

^b Res Grp Diabet/Chron Illnesses   (Mexico)

^c NONE   (Mexico)

Author keywords

C Reactive Protein; Dyslipidemia High Blood Pressure; Metabolic Syndrome; Micoalbuminuria; Obesity

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIET RESTRICTION; DYSLIPIDEMIA; FEMALE; GLUCOSE TOLERANCE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY;

EID: 0037302254     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70009-5     Document Type: Article

References (50)

1. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia, and atherosclerotic cardiovascular disease. Diabetes Care, 1991, 14, 173-94.
2. Ferrannini E. Physiological and metabolic consequences of obesity. Metabolism, 1995, 44, 15-7.
3. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia, 1991, 34, 416-22.
4. Alberti KGMM, Zimmet PZ for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med, 1998, 5, 53-9.
5. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 2001, 24, 683-9.
6. Kaplan NM. The deadly quartet: upper body adiposity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med, 1989, 149, 1514-20.
7. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia, 1997, 40, 1286-92.
8. Pannacciulli N, Cantatore FP, Minenna A, Bellacicco M, Giogino R, De Pergola G. C-reactive protein is independently associated with total body fat, central fat, and insulin resistanse in adult women. Int J Obes Relat Metab Disord, 2001, 25, 1416-20.
9. Forohui NG, Sattar N, McKeigue PM. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes Relat Metab Disord, 2001, 25, 1327-31.
10. Festa A, D'Agostino RJr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation, 2000, 102, 42-7.
11. Blackburn R, Giral P, Bruckert E, et al. Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects. Arterioscler Thromb Vasc Biol, 2001, 21, 1962-8.
12. Frolich M, Imhof A, Berg G, et al. association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care, 2000, 23, 1835-9.
13. Le Marchand-Brustel Y. Molecular mechanisms of insulin action in normal and insulin-resistant states. Exp Clin Endocrinol Diabetes, 1999, 107, 26-32.
14. Mishima Y, Kuyama A, Tada A, Takahashi K, Ishioka T, Kibata M. Relationship between serum tumor necrosis factor-alpha and insulin resistance in obese men with Type 2 diabetes mellitus. Diabetes Res Clin Pract, 2001, 52, 119-23.
15. Hauner H, Bender M, Haastert B, Hube F. Plasma concentrations of soluble TNF-alpha receptors in obese subjects. Int J Obes Relat Metab Disord, 1998, 22, 1239-43.
16. rd edn. Oxford University Press: Oxford; 1995, 1527-33.
17. Tracy RP, Psaty MB, Macy E, et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Aterioscler Thromb Vasc Biol, 1997, 17, 2167-76.
18. Ridker PM, Hennekens CH, Buring JE, Rifai N. C reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 2000, 342, 836-43.
19. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med, 1997, 336, 973-9.
20. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study: Multiple risk factor intervention trial. Am J Epidemiol, 1996, 144, 537-47.
21. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol, 1997, 17, 1121-7.
22. Nieto FJ, Adam E, Sorlie P, et al. Cohort study of cytomegalovirus infection as a risk for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation, 1996, 94, 922-7.
23. Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care, 1999, 22, 1971-7.
24. Warren RS, Starnes HF Jr, Gabrilove JL, Oettgen HF, Brennan MF. The acute metabolic effects of tumor necrosis factor administration in human. Arch Surg, 1987, 122, 1396-400.
25. Baumann H, Gauldie J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med, 1990, 7, 147-59.
26. Guerrero-Romero F, Rodríguez Morán M, Paniagua-Sierra JR, Garcia-Bulnes G, Salas-Ramírez M, Amato D. Pentoxifylline reduces proteinuria in insulin dependent and non insulin-dependent diabetic patients. Clin Nephrol, 1995, 43, 116-21.
27. Guerrero-Romero F, Rodríguez-Morán M. Relationship between serum magnesium levels and C-reactive protein concentration, in non-diabetic, non-hypertensive obese subjects. Int J Obes Relat Metab Disord, 2002, 26, 469-74.
28. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 1999, 22, S5-S19.
29. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med, 1997, 157, 2413-46.
30. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis Model Assessment: Insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985, 28, 412-9.
31. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic values of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med, 1994, 331, 417-24.
32. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk ofmyoeardial infarction or sudden death in patients with angina pectoris. N Engl J Med, 1995, 332, 635-41.
33. Koenig W, Sund M, Frölich M, et al. C-Reactive protein, a sensitive marker of inflammation predicts future risk of coronary heart disease in initially healthy middle-aged men. Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Ausburg Cohort Study, 1984 to 1992. Circulation, 1999, 99, 237-42.
34. Kuller H, Tracy RP, Shaten I, Meilahn EN, for the MRFIT Research Group. Relation of q-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol, 1996, 144, 537-47.
35. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-Reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vase Biol, 1999, 19, 972-8.
36. Patel P, Mendall MA, Carrington D, et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk. BMJ, 1995, 311, 711-4.
37. Libby P, Rgan D, Skarlatos S. Roles of infectious agents in atherosclerosis and estenosis. An assessment of the evidence and need for future research. Circulation, 1997, 96, 4095-103.
38. Koenig W, Wanner Ch. C-Reactive protein and coronary artery disease - what is the link?. Neprhol Dial Transplant, 1999, 14, 2798-800.
39. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J, 1990, 265, 621-36.
40. Myrup B, de Maat M, Rossing P, Gram J, Kluft C, Jespersen J. Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. Thromb Res 1996, 81, 485-90.
41. Stephens JM, Butts MD, Pekala PH. Regulation of transcription factor mRNA acummulation during 3T3-L1 preadypocite differentation by tumor necrosis factor-alpha. J Mol Endocrinol, 1992, 61-72.
42. Ebeling P, Teppo AM, Koistinen HA, Koivisto VA. Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes. Metabolism, 2001,50, 283-7.
43. Rodríguez-Morán M, Guerrero-Romero F. Increased levels of C-reactive protein in Non-controlled Type 2 Diabetic subjects. J Diabetes Complications, 1999,13, 211-5.
44. Margaglione M, Cappucci G, Colaizzo D, Vecchione G, Grandone E, Di Minno G. C-Reactive protein in offspring is associated with the occurrence of myocardial infarction in first-degree relatives. Arterioscler Thromb Vasc Biol, 2000, 20, 198-203.
45. Mendall MA, Patel B, Ballam L, Strachan D, Northfield TC. C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ, 1996, 312, 1061-5.
46. Li JJ, Jiang H, Huang CX, et al. Elevated level of plasma C-reactive protein in patients with unstable angina: its relations with coronary stenosis and lipid profile. Angiology, 2002, 53, 265-72.
47. Hak AE, Stehouuwer DA, Bots ML, et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol, 1999, 19, 1986-91.
48. Temelkova-Kurktschiev T, Siegert G, Bergmann S, et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism, 2002, 51, 743-9.
49. Deckert T, Feldt-Rasmussen B, Boreh-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: The steno hypothesis. Diabetologia, 1989, 32, 219-26.
50. Savage S, Estacio RO, Jeffers B, Schrier RW. Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care, 1996, 19, 1243-8.